-
1
-
-
73549115378
-
Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989-2009)
-
M.-P. de Béthune Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009) Antivir. Res. 85 2010 75 90
-
(2010)
Antivir. Res.
, vol.85
, pp. 75-90
-
-
De Béthune, M.-P.1
-
2
-
-
84862580827
-
In search of a treatment for HIV-current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs)
-
C. Reynolds, C.B. de Koning, S.C. Pelly, W.A. van Otterlo, and M.L. Bode In search of a treatment for HIV-current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) Chem. Soc. Rev. 41 2012 4657 4670
-
(2012)
Chem. Soc. Rev.
, vol.41
, pp. 4657-4670
-
-
Reynolds, C.1
De Koning, C.B.2
Pelly, S.C.3
Van Otterlo, W.A.4
Bode, M.L.5
-
3
-
-
0032437454
-
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
-
E. De Clercq The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection Antivir. Res. 38 1998 153 179
-
(1998)
Antivir. Res.
, vol.38
, pp. 153-179
-
-
De Clercq, E.1
-
4
-
-
84876852661
-
HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design
-
P. Zhan, X. Chen, D. Li, Z. Fang, E. De Clercq, and X. Liu HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design Med. Res. Rev. 33 2011 E1 E72
-
(2011)
Med. Res. Rev.
, vol.33
-
-
Zhan, P.1
Chen, X.2
Li, D.3
Fang, Z.4
De Clercq, E.5
Liu, X.6
-
5
-
-
1542471588
-
Nonnucleoside HIV-1 reverse transcriptase inhibitors: Part I. Synthesis and structure-activity relationship of 1-alkoxymethyl-5-alkyl-6-naphthylmethyl uracils as HEPT analogues
-
G. Meng, F. Chen, E. De Clercq, J. Balzarini, and C. Pannecouque Nonnucleoside HIV-1 reverse transcriptase inhibitors: part I. synthesis and structure-activity relationship of 1-alkoxymethyl-5-alkyl-6-naphthylmethyl uracils as HEPT analogues Chem. Pharm. Bull. (Tokyo) 51 2003 779 789
-
(2003)
Chem. Pharm. Bull. (Tokyo)
, vol.51
, pp. 779-789
-
-
Meng, G.1
Chen, F.2
De Clercq, E.3
Balzarini, J.4
Pannecouque, C.5
-
7
-
-
60549105209
-
Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors
-
Y.-P. Wang, F.-E. Chen, E. De Clercq, J. Balzarini, and C. Pannecouque Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors Eur. J. Med. Chem. 44 2009 1016 1023
-
(2009)
Eur. J. Med. Chem.
, vol.44
, pp. 1016-1023
-
-
Wang, Y.-P.1
Chen, F.-E.2
De Clercq, E.3
Balzarini, J.4
Pannecouque, C.5
-
8
-
-
2442610540
-
5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series
-
Y. He, F. Chen, G. Sun, Y. Wang, E. De Clercq, J. Balzarini, and C. Pannecouque 5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1- naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series Bioorg. Med. Chem. Lett. 14 2004 3173 3176
-
(2004)
Bioorg. Med. Chem. Lett.
, vol.14
, pp. 3173-3176
-
-
He, Y.1
Chen, F.2
Sun, G.3
Wang, Y.4
De Clercq, E.5
Balzarini, J.6
Pannecouque, C.7
-
9
-
-
17944374798
-
Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues
-
D.W. Ludovici, B.L. De Corte, M.J. Kukla, H. Ye, C.Y. Ho, M.A. Lichtenstein, R.W. Kavash, K. Andries, M.-P. de Béthune, and H. Azijn Evolution of anti-HIV drug candidates. part 3: diarylpyrimidine (DAPY) analogues Bioorg. Med. Chem. Lett. 11 2001 2235 2239
-
(2001)
Bioorg. Med. Chem. Lett.
, vol.11
, pp. 2235-2239
-
-
Ludovici, D.W.1
De Corte, B.L.2
Kukla, M.J.3
Ye, H.4
Ho, C.Y.5
Lichtenstein, M.A.6
Kavash, R.W.7
Andries, K.8
De Béthune, M.-P.9
Azijn, H.10
-
10
-
-
80051594199
-
Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase
-
H. Zhang, F. Qin, W. Ye, Z. Li, S. Ma, Y. Xia, Y. Jiang, J. Zhu, Y. Li, and J. Zhang Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase Chem. Biol. Drug Des. 78 2011 427 437
-
(2011)
Chem. Biol. Drug Des.
, vol.78
, pp. 427-437
-
-
Zhang, H.1
Qin, F.2
Ye, W.3
Li, Z.4
Ma, S.5
Xia, Y.6
Jiang, Y.7
Zhu, J.8
Li, Y.9
Zhang, J.10
-
11
-
-
84878004314
-
Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors
-
S.-Q. Yang, C. Pannecouque, D. Daelemans, X.-D. Ma, Y. Liu, F.-E. Chen, and E. De Clercq Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors Eur. J. Med. Chem. 65C 2013 134 143
-
(2013)
Eur. J. Med. Chem.
, vol.65 C
, pp. 134-143
-
-
Yang, S.-Q.1
Pannecouque, C.2
Daelemans, D.3
Ma, X.-D.4
Liu, Y.5
Chen, F.-E.6
De Clercq, E.7
-
12
-
-
12144265244
-
Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present, and future
-
E. De Clercq Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future Chem. Biodivers. 1 2004 44 64
-
(2004)
Chem. Biodivers.
, vol.1
, pp. 44-64
-
-
De Clercq, E.1
-
13
-
-
0032514718
-
Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives
-
J. Ren, R.M. Esnouf, A.L. Hopkins, J. Warren, J. Balzarini, D.I. Stuart, and D.K. Stammers Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives Biochemistry 37 1998 14394 14403
-
(1998)
Biochemistry
, vol.37
, pp. 14394-14403
-
-
Ren, J.1
Esnouf, R.M.2
Hopkins, A.L.3
Warren, J.4
Balzarini, J.5
Stuart, D.I.6
Stammers, D.K.7
-
14
-
-
36849047420
-
Crystal structures of HIV-1 reverse transcriptase complexes with thiocarbamate non-nucleoside inhibitors
-
A. Spallarossa, S. Cesarini, A. Ranise, M. Ponassi, T. Unge, and M. Bolognesi Crystal structures of HIV-1 reverse transcriptase complexes with thiocarbamate non-nucleoside inhibitors Biochem. Biophys. Res. Commun. 365 2008 764 770
-
(2008)
Biochem. Biophys. Res. Commun.
, vol.365
, pp. 764-770
-
-
Spallarossa, A.1
Cesarini, S.2
Ranise, A.3
Ponassi, M.4
Unge, T.5
Bolognesi, M.6
-
15
-
-
50249149488
-
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors
-
J. Ren, P.P. Chamberlain, A. Stamp, S.A. Short, K.L. Weaver, K.R. Romines, R. Hazen, A. Freeman, R.G. Ferris, C.W. Andrews, L. Boone, J.H. Chan, and D.K. Stammers Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors J. Med. Chem. 51 2008 5000 5008
-
(2008)
J. Med. Chem.
, vol.51
, pp. 5000-5008
-
-
Ren, J.1
Chamberlain, P.P.2
Stamp, A.3
Short, S.A.4
Weaver, K.L.5
Romines, K.R.6
Hazen, R.7
Freeman, A.8
Ferris, R.G.9
Andrews, C.W.10
Boone, L.11
Chan, J.H.12
Stammers, D.K.13
-
16
-
-
0027278282
-
Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: Structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1- methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second generation clinical candidate
-
D.L. Romero, R.A. Morge, M.J. Genin, C. Biles, M. Busso, L. Resnick, I.W. Althaus, F. Reusser, R.C. Thomas, and W.G. Tarpley Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1-methylethyl)amino] -pyridinyl]piperazine monomethanesulfonate (U-90152S), a second generation clinical candidate J. Med. Chem. 36 1993 1505 1508
-
(1993)
J. Med. Chem.
, vol.36
, pp. 1505-1508
-
-
Romero, D.L.1
Morge, R.A.2
Genin, M.J.3
Biles, C.4
Busso, M.5
Resnick, L.6
Althaus, I.W.7
Reusser, F.8
Thomas, R.C.9
Tarpley, W.G.10
-
17
-
-
77649163883
-
IDX-899, an aryl phosphinate-indole non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection
-
O.M. Klibanov, and R.L. Kaczor IDX-899, an aryl phosphinate-indole non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection Curr. Opin. Investig. Drugs 11 2010 237 245
-
(2010)
Curr. Opin. Investig. Drugs
, vol.11
, pp. 237-245
-
-
Klibanov, O.M.1
Kaczor, R.L.2
-
18
-
-
20144366006
-
Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1
-
J. Guillemont, E. Pasquier, P. Palandjian, D. Vernier, S. Gaurrand, P.J. Lewi, J. Heeres, M.R. de Jonge, L.M. Koymans, F.F. Daeyaert, M.H. Vinkers, E. Arnold, K. Das, R. Pauwels, K. Andries, M.P. de Béthune, E. Bettens, K. Hertogs, P. Wigerinck, P. Timmerman, and P.A. Janssen Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1 J. Med. Chem. 48 2005 2072 2079
-
(2005)
J. Med. Chem.
, vol.48
, pp. 2072-2079
-
-
Guillemont, J.1
Pasquier, E.2
Palandjian, P.3
Vernier, D.4
Gaurrand, S.5
Lewi, P.J.6
Heeres, J.7
De Jonge, M.R.8
Koymans, L.M.9
Daeyaert, F.F.10
Vinkers, M.H.11
Arnold, E.12
Das, K.13
Pauwels, R.14
Andries, K.15
De Béthune, M.P.16
Bettens, E.17
Hertogs, K.18
Wigerinck, P.19
Timmerman, P.20
Janssen, P.A.21
more..
-
19
-
-
34347354196
-
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
-
A. Lazzarin, T. Campbell, B. Clotet, M. Johnson, C. Katlama, A. Moll, W. Towner, B. Trottier, M. Peeters, J. Vingerhoets, G. de Smedt, B. Baeten, G. Beets, R. Sinha, and B. Woodfall Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 2007 39 48
-
(2007)
Lancet
, vol.370
, pp. 39-48
-
-
Lazzarin, A.1
Campbell, T.2
Clotet, B.3
Johnson, M.4
Katlama, C.5
Moll, A.6
Towner, W.7
Trottier, B.8
Peeters, M.9
Vingerhoets, J.10
De Smedt, G.11
Baeten, B.12
Beets, G.13
Sinha, R.14
Woodfall, B.15
-
20
-
-
34347327010
-
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
-
J.V. Madruga, P. Cahn, B. Grinsztejn, R. Haubrich, J. Lalezari, A. Mills, G. Pialoux, T. Wilkin, M. Peeters, J. Vingerhoets, G. de Smedt, L. Leopold, R. Trefiglio, and B. Woodfall Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 2007 29 38
-
(2007)
Lancet
, vol.370
, pp. 29-38
-
-
Madruga, J.V.1
Cahn, P.2
Grinsztejn, B.3
Haubrich, R.4
Lalezari, J.5
Mills, A.6
Pialoux, G.7
Wilkin, T.8
Peeters, M.9
Vingerhoets, J.10
De Smedt, G.11
Leopold, L.12
Trefiglio, R.13
Woodfall, B.14
-
21
-
-
50849108264
-
Shifting paradigms: The resistance profile of etravirine
-
A.M. Geretti Shifting paradigms: the resistance profile of etravirine J. Antimicrob. Chemother. 62 2008 643 647
-
(2008)
J. Antimicrob. Chemother.
, vol.62
, pp. 643-647
-
-
Geretti, A.M.1
-
22
-
-
79251472419
-
Recent advances in DAPYs and related analogues as HIV-1 NNRTIs
-
X. Chen, P. Zhan, D. Li, E. De Clercq, and X. Liu Recent advances in DAPYs and related analogues as HIV-1 NNRTIs Curr. Med. Chem. 18 2011 359 376
-
(2011)
Curr. Med. Chem.
, vol.18
, pp. 359-376
-
-
Chen, X.1
Zhan, P.2
Li, D.3
De Clercq, E.4
Liu, X.5
-
23
-
-
20144372481
-
In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)
-
P.A. Janssen, P.J. Lewi, E. Arnold, F. Daeyaert, M. De Jonge, J. Heeres, L. Koymans, M. Vinkers, J. Guillemont, E. Pasquier, M. Kukla, D. Ludovici, K. Andries, M.P. de Béthune, R. Pauwels, K. Das, A.D. Clark Jr., Y.V. Frenkel, S.H. Hughes, B. Medaer, F. De Knaep, H. Bohets, F. De Clerck, A. Lampo, P. Williams, and P. Stoffels In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2- cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine) J. Med. Chem. 48 2005 1901 1909
-
(2005)
J. Med. Chem.
, vol.48
, pp. 1901-1909
-
-
Janssen, P.A.1
Lewi, P.J.2
Arnold, E.3
Daeyaert, F.4
De Jonge, M.5
Heeres, J.6
Koymans, L.7
Vinkers, M.8
Guillemont, J.9
Pasquier, E.10
Kukla, M.11
Ludovici, D.12
Andries, K.13
De Béthune, M.P.14
Pauwels, R.15
Das, K.16
Clark, Jr.A.D.17
Frenkel, Y.V.18
Hughes, S.H.19
Medaer, B.20
De Knaep, F.21
Bohets, H.22
De Clerck, F.23
Lampo, A.24
Williams, P.25
Stoffels, P.26
more..
-
24
-
-
67449119172
-
Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment
-
L. Baert, G. van't Klooster, W. Dries, M. Francois, A. Wouters, E. Basstanie, K. Iterbeke, F. Stappers, P. Stevens, L. Schueller, P. Van Remoortere, G. Kraus, P. Wigerinck, and J. Rosier Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment Eur. J. Pharm. Biopharm. 72 2009 502 508
-
(2009)
Eur. J. Pharm. Biopharm.
, vol.72
, pp. 502-508
-
-
Baert, L.1
Van'T Klooster, G.2
Dries, W.3
Francois, M.4
Wouters, A.5
Basstanie, E.6
Iterbeke, K.7
Stappers, F.8
Stevens, P.9
Schueller, L.10
Van Remoortere, P.11
Kraus, G.12
Wigerinck, P.13
Rosier, J.14
-
25
-
-
40349091258
-
High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations
-
K. Das, J.D. Bauman, A.D. Clark, Y.V. Frenkel, P.J. Lewi, A.J. Shatkin, S.H. Hughes, and E. Arnold High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations Proc. Natl. Acad. Sci. U. S. A. 105 2008 1466 1471
-
(2008)
Proc. Natl. Acad. Sci. U. S. A.
, vol.105
, pp. 1466-1471
-
-
Das, K.1
Bauman, J.D.2
Clark, A.D.3
Frenkel, Y.V.4
Lewi, P.J.5
Shatkin, A.J.6
Hughes, S.H.7
Arnold, E.8
-
26
-
-
50849105061
-
Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design
-
J.D. Bauman, K. Das, W.C. Ho, M. Baweja, D.M. Himmel, A.D. Clark, D.A. Oren, P.L. Boyer, S.H. Hughes, and A.J. Shatkin Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design Nucleic Acids Res. 36 2008 5083 5092
-
(2008)
Nucleic Acids Res.
, vol.36
, pp. 5083-5092
-
-
Bauman, J.D.1
Das, K.2
Ho, W.C.3
Baweja, M.4
Himmel, D.M.5
Clark, A.D.6
Oren, D.A.7
Boyer, P.L.8
Hughes, S.H.9
Shatkin, A.J.10
-
27
-
-
77952724079
-
Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): Implications for drug design
-
E.B. Lansdon, K.M. Brendza, M. Hung, R. Wang, S. Mukund, D. Jin, G. Birkus, N. Kutty, and X. Liu Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design J. Med. Chem. 53 2010 4295 4299
-
(2010)
J. Med. Chem.
, vol.53
, pp. 4295-4299
-
-
Lansdon, E.B.1
Brendza, K.M.2
Hung, M.3
Wang, R.4
Mukund, S.5
Jin, D.6
Birkus, G.7
Kutty, N.8
Liu, X.9
-
28
-
-
79952608410
-
Rational approaches for the design of effective human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitors
-
S.R. Ribone, M.A. Quevedo, M. Madrid, and M.C. BrinoÍn Rational approaches for the design of effective human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitors J. Chem. Inf. Model. 51 2010 130 138
-
(2010)
J. Chem. Inf. Model.
, vol.51
, pp. 130-138
-
-
Ribone, S.R.1
Quevedo, M.A.2
Madrid, M.3
Brinoín, M.C.4
-
29
-
-
78649854734
-
Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors
-
X. Tian, B. Qin, Z. Wu, X. Wang, H. Lu, S.L. Morris-Natschke, C.H. Chen, S. Jiang, K.-H. Lee, and L. Xie Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors J. Med. Chem. 53 2010 8287 8297
-
(2010)
J. Med. Chem.
, vol.53
, pp. 8287-8297
-
-
Tian, X.1
Qin, B.2
Wu, Z.3
Wang, X.4
Lu, H.5
Morris-Natschke, S.L.6
Chen, C.H.7
Jiang, S.8
Lee, K.-H.9
Xie, L.10
-
30
-
-
2342620790
-
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants
-
K. Das, A.D. Clark Jr., P.J. Lewi, J. Heeres, M.R. De Jonge, L.M. Koymans, H.M. Vinkers, F. Daeyaert, D.W. Ludovici, M.J. Kukla, B. De Corte, R.W. Kavash, C.Y. Ho, H. Ye, M.A. Lichtenstein, K. Andries, R. Pauwels, M.P. de Béthune, P.L. Boyer, P. Clark, S.H. Hughes, P.A. Janssen, and E. Arnold Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants J. Med. Chem. 47 2004 2550 2560
-
(2004)
J. Med. Chem.
, vol.47
, pp. 2550-2560
-
-
Das, K.1
Clark, Jr.A.D.2
Lewi, P.J.3
Heeres, J.4
De Jonge, M.R.5
Koymans, L.M.6
Vinkers, H.M.7
Daeyaert, F.8
Ludovici, D.W.9
Kukla, M.J.10
De Corte, B.11
Kavash, R.W.12
Ho, C.Y.13
Ye, H.14
Lichtenstein, M.A.15
Andries, K.16
Pauwels, R.17
De Béthune, M.P.18
Boyer, P.L.19
Clark, P.20
Hughes, S.H.21
Janssen, P.A.22
Arnold, E.23
more..
-
31
-
-
77953089657
-
Lead optimization of diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase
-
Z.-S. Zeng, Y.-H. Liang, X.-Q. Feng, F.-E. Chen, C. Pannecouque, J. Balzarini, and E. De Clercq Lead optimization of diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase ChemMedChem 5 2010 837 840
-
(2010)
ChemMedChem
, vol.5
, pp. 837-840
-
-
Zeng, Z.-S.1
Liang, Y.-H.2
Feng, X.-Q.3
Chen, F.-E.4
Pannecouque, C.5
Balzarini, J.6
De Clercq, E.7
-
32
-
-
77950037962
-
Synthesis and biological evaluation of 4-(hydroxyimino) arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV
-
X.-Q. Feng, Z.-S. Zeng, Y.-H. Liang, F.-E. Chen, C. Pannecouque, J. Balzarini, and E. De Clercq Synthesis and biological evaluation of 4-(hydroxyimino) arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV Bioorg. Med. Chem. 18 2010 2370 2374
-
(2010)
Bioorg. Med. Chem.
, vol.18
, pp. 2370-2374
-
-
Feng, X.-Q.1
Zeng, Z.-S.2
Liang, Y.-H.3
Chen, F.-E.4
Pannecouque, C.5
Balzarini, J.6
De Clercq, E.7
-
33
-
-
34248397581
-
Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains
-
C. Mordant, B. Schmitt, E. Pasquier, C. Demestre, L. Queguiner, C. Masungi, A. Peeters, L. Smeulders, E. Bettens, and K. Hertogs Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains Eur. J. Med. Chem. 42 2007 567 579
-
(2007)
Eur. J. Med. Chem.
, vol.42
, pp. 567-579
-
-
Mordant, C.1
Schmitt, B.2
Pasquier, E.3
Demestre, C.4
Queguiner, L.5
Masungi, C.6
Peeters, A.7
Smeulders, L.8
Bettens, E.9
Hertogs, K.10
-
34
-
-
84904216103
-
-
in press
-
Y. Liu, G. Meng, A. Zheng, F. Chen, W. Chen, E. De Clercq, C. Pannecouque, and J. Balzarini Design and Synthesis of a New Series of Cyclopropylamino-linking Diarylpyrimidines as HIV Non-nucleoside Reverse Transcriptase Inhibitors Europ. J. Pharm. Sci. 2014 in press
-
(2014)
Design and Synthesis of A New Series of Cyclopropylamino-linking Diarylpyrimidines As HIV Non-nucleoside Reverse Transcriptase Inhibitors Europ. J. Pharm. Sci.
-
-
Liu, Y.1
Meng, G.2
Zheng, A.3
Chen, F.4
Chen, W.5
De Clercq, E.6
Pannecouque, C.7
Balzarini, J.8
-
35
-
-
82955165647
-
Synthesis and anti-HIV activity of aryl-2-[(4-cyanophenyl) amino]-4-pyrimidinone hydrazones as potent non-nucleoside reverse transcriptase inhibitors
-
X.-D. Ma, S.-Q. Yang, S.-X. Gu, Q.-Q. He, F.-E. Chen, E. De Clercq, J. Balzarini, and C. Pannecouque Synthesis and anti-HIV activity of aryl-2-[(4-cyanophenyl) amino]-4-pyrimidinone hydrazones as potent non-nucleoside reverse transcriptase inhibitors ChemMedChem 6 2011 2225 2232
-
(2011)
ChemMedChem
, vol.6
, pp. 2225-2232
-
-
Ma, X.-D.1
Yang, S.-Q.2
Gu, S.-X.3
He, Q.-Q.4
Chen, F.-E.5
De Clercq, E.6
Balzarini, J.7
Pannecouque, C.8
-
36
-
-
84861632263
-
Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors
-
S.-X. Gu, Z.-M. Li, X.-D. Ma, S.-Q. Yang, Q.-Q. He, F.-E. Chen, E. De Clercq, J. Balzarini, and C. Pannecouque Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors Eur. J. Med. Chem. 53 2012 229 234
-
(2012)
Eur. J. Med. Chem.
, vol.53
, pp. 229-234
-
-
Gu, S.-X.1
Li, Z.-M.2
Ma, X.-D.3
Yang, S.-Q.4
He, Q.-Q.5
Chen, F.-E.6
De Clercq, E.7
Balzarini, J.8
Pannecouque, C.9
-
37
-
-
84860390578
-
Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs
-
S.-X. Gu, Q.-Q. He, S.-Q. Yang, X.-D. Ma, F.-E. Chen, E. De Clercq, J. Balzarini, and C. Pannecouque Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs Bioorg. Med. Chem. 19 2011 5117 5124
-
(2011)
Bioorg. Med. Chem.
, vol.19
, pp. 5117-5124
-
-
Gu, S.-X.1
He, Q.-Q.2
Yang, S.-Q.3
Ma, X.-D.4
Chen, F.-E.5
De Clercq, E.6
Balzarini, J.7
Pannecouque, C.8
-
38
-
-
60849096957
-
Structural modifications of DAPY analogues with potent anti-HIV-1 activity
-
X.-Q. Feng, Y.-H. Liang, Z.-S. Zeng, F.-E. Chen, J. Balzarini, C. Pannecouque, and E. De Clercq Structural modifications of DAPY analogues with potent anti-HIV-1 activity ChemMedChem 4 2009 219 224
-
(2009)
ChemMedChem
, vol.4
, pp. 219-224
-
-
Feng, X.-Q.1
Liang, Y.-H.2
Zeng, Z.-S.3
Chen, F.-E.4
Balzarini, J.5
Pannecouque, C.6
De Clercq, E.7
-
40
-
-
9744258219
-
Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors
-
K. Das, P.J. Lewi, S.H. Hughes, and E. Arnold Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors Prog. Biophys. Mol. Biol. 88 2005 209 231
-
(2005)
Prog. Biophys. Mol. Biol.
, vol.88
, pp. 209-231
-
-
Das, K.1
Lewi, P.J.2
Hughes, S.H.3
Arnold, E.4
-
41
-
-
20144368570
-
Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives
-
A. Ranise, A. Spallarossa, S. Cesarini, F. Bondavalli, S. Schenone, O. Bruno, G. Menozzi, P. Fossa, L. Mosti, and M. La Colla Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives J. Med. Chem. 48 2005 3858 3873
-
(2005)
J. Med. Chem.
, vol.48
, pp. 3858-3873
-
-
Ranise, A.1
Spallarossa, A.2
Cesarini, S.3
Bondavalli, F.4
Schenone, S.5
Bruno, O.6
Menozzi, G.7
Fossa, P.8
Mosti, L.9
La Colla, M.10
-
42
-
-
40749129190
-
Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: Revisited 20 years later
-
C. Pannecouque, D. Daelemans, and E. De Clercq Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later Nat. Protoc. 3 2008 427 434
-
(2008)
Nat. Protoc.
, vol.3
, pp. 427-434
-
-
Pannecouque, C.1
Daelemans, D.2
De Clercq, E.3
-
43
-
-
0023687234
-
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
-
R. Pauwels, J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds J. Virol. Methods 20 1988 309 321
-
(1988)
J. Virol. Methods
, vol.20
, pp. 309-321
-
-
Pauwels, R.1
Balzarini, J.2
Baba, M.3
Snoeck, R.4
Schols, D.5
Herdewijn, P.6
Desmyter, J.7
De Clercq, E.8
-
44
-
-
0036156328
-
Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: Role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors
-
J. Auwerx, T.W. North, B.D. Preston, G.J. Klarmann, E. De Clercq, and J. Balzarini Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors Mol. Pharmacol. 61 2002 400 406
-
(2002)
Mol. Pharmacol.
, vol.61
, pp. 400-406
-
-
Auwerx, J.1
North, T.W.2
Preston, B.D.3
Klarmann, G.J.4
De Clercq, E.5
Balzarini, J.6
-
45
-
-
0031194671
-
Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation
-
V.L. Singer, L.J. Jones, S.T. Yue, and R.P. Haugland Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation Anal. Biochem. 249 1997 228 238
-
(1997)
Anal. Biochem.
, vol.249
, pp. 228-238
-
-
Singer, V.L.1
Jones, L.J.2
Yue, S.T.3
Haugland, R.P.4
-
46
-
-
84865214371
-
Surflex-Dock: Docking benchmarks and real-world application
-
R. Spitzer, and A.N. Jain Surflex-Dock: docking benchmarks and real-world application J. Comput. Aided Mol. Des. 26 2012 687 699
-
(2012)
J. Comput. Aided Mol. Des.
, vol.26
, pp. 687-699
-
-
Spitzer, R.1
Jain, A.N.2
-
47
-
-
34247343346
-
Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search
-
A.N. Jain Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search J. Comput. Aided Mol. Des. 21 2007 281 306
-
(2007)
J. Comput. Aided Mol. Des.
, vol.21
, pp. 281-306
-
-
Jain, A.N.1
-
48
-
-
0037434582
-
Surflex: Fully automatic flexible molecular docking using a molecular similarity-based search engine
-
A.N. Jain Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine J. Med. Chem. 46 2003 499 511
-
(2003)
J. Med. Chem.
, vol.46
, pp. 499-511
-
-
Jain, A.N.1
-
49
-
-
0030979125
-
Automatic identification and representation of protein binding sites for molecular docking
-
J. Ruppert, W. Welch, and A.N. Jain Automatic identification and representation of protein binding sites for molecular docking Protein Sci. 6 1997 524 533
-
(1997)
Protein Sci.
, vol.6
, pp. 524-533
-
-
Ruppert, J.1
Welch, W.2
Jain, A.N.3
|